Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RYTM Rhythm Pharmaceuticals Inc.

Pre-Mkt 06-10 06:02:36 EDT

87.86

+1.94

+2.25%

盘前86.00

-1.86-2.12%

04:02 EDT

High90.14	Low84.73	Vol626.44K
Open87.65	D1 Closing85.93	Amplitude6.30%
Mkt Cap6.00B	Tradable Cap4.87B	Total Shares68.29M
T/O54.74M	T/O Rate1.13%	Tradable Shares55.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RYTM","market":"US","secType":"STK","nameCN":"Rhythm Pharmaceuticals Inc.","latestPrice":87.86,"timestamp":1781035200000,"preClose":85.925,"halted":0,"volume":626441,"hourTrading":{"tag":"盘前","latestPrice":86,"preClose":87.86,"latestTime":"04:02 EDT","volume":3,"amount":258,"timestamp":1781078552664,"change":-1.86,"changeRate":-0.02117,"amplitude":0},"delay":0,"changeRate":0.022519639220250246,"floatShares":55477500,"shares":68285039,"eps":-3.138955,"marketStatus":"Pre-Mkt","change":1.935,"latestTime":"06-10 06:02:36 EDT","open":87.65,"high":90.14,"low":84.73,"amount":54741559.31382,"amplitude":0.062962,"askPrice":97.85,"askSize":100,"bidPrice":78.65,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.138955,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1781098200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1507176000000,"exchange":"NASDAQ","adjPreClose":87.86,"preHourTrading":{"tag":"盘前","latestPrice":86,"preClose":87.86,"latestTime":"04:02 EDT","volume":3,"amount":258,"timestamp":1781078552664,"change":-1.86,"changeRate":-0.02117,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":87.86,"preClose":87.86,"latestTime":"16:48 EDT","volume":28211,"amount":2478616.76,"timestamp":1781038110813,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3733825877853354,"impliedVol":0.7917,"impliedVolPercentile":0.892},"requestUrl":"/m/hq/s/RYTM","defaultTab":"news","newsList":[{"id":"2639460315","title":"Rhythm Algorithm Aims To Clarify Bardet Biedl Diagnosis And Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2639460315","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639460315?lang=en_us&edition=fundamental","pubTime":"2026-05-30 09:05","pubTimestamp":1780103146,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (NasdaqGM:RYTM) has published a new evidence-based diagnostic algorithm for Bardet-Biedl syndrome.\nThe algorithm is designed to streamline and accelerate clinical diagnosis of this rare obesity disorder.\nThe update incorporates recent advances in genetic testing to support earlier and more accurate identification of BBS.\n\nRhythm Pharmaceuticals focuses on treatments for rare genetic forms of obesity, and Bardet-Biedl syndrome is a core part of that remit. A clearer...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-algorithm-aims-to-clarify-bardet-biedl-diagnosis-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-algorithm-aims-to-clarify-bardet-biedl-diagnosis-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4139","BK4588","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638169878","title":"Rhythm Pharma hosts inaugural MOMENTUM MC4R Pathway Summit featuring updated BBS diagnostic algorithm presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2638169878","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638169878?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:07","pubTimestamp":1779970061,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals will host its inaugural MOMENTUM MC4R Pathway Summit on June 12 in Chicago.Brooke Sweeney, MD, will present an updated Bardet-Biedl syndrome diagnostic algorithm at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL7cWZhP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","RYTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638523008","title":"Rhythm Pharma releases corporate presentation on MC4R agonist pipeline for rare obesity disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2638523008","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638523008?lang=en_us&edition=fundamental","pubTime":"2026-05-27 05:50","pubTimestamp":1779832244,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals highlighted IMCIVREE as the only approved therapy for acquired hypothalamic obesity, citing Phase 3 BMI change of -16.4% at 52 weeks.Placebo arm showed +2.4% BMI change; placebo-adjusted difference was -18.8% with P<0.0001 in the primary analysis cohort of 142 patients.U.S. launch metrics as of May 1, 2026: more than 150 patient start forms, about 110 unique prescribers, about 80% new prescribers.Cash, cash equivalents, short-term investments totaled $340.6 million as of March 31, 2026; 68 million common shares outstanding as of May 1, 2026.Pipeline focus on next-generation MC4R agonists; pivotal Phase 3 start for oral bivamelagon in acquired hypothalamic obesity targeted for year-end 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inve","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL8C71Qn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RYTM","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638511745","title":"Rhythm Pharma CFO to speak at Jefferies Global Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2638511745","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638511745?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:00","pubTimestamp":1779796842,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals to join a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026 at 12:50 p.m. ET.CEO David Meeker to appear in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026 at 1:20 p.m. ET.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL1mPxv3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","LU2750360997.AUD","LU2237443465.HKD","BK4516","LU0251131958.USD","LU1868836757.USD","LU2237443622.USD","RYTM","IE0004091025.USD","LU0345770308.USD","LU2265009873.SGD","IE00BN0W2V16.EUR","NDAQ","IE0004086264.USD","LU2237443382.USD","SG9999014039.USD","LU2750360641.GBP","BK4552","IE00BSNM7G36.USD","BK4112","LU1668664300.SGD","LU2237438978.USD","LU2471134879.HKD","LU0096364046.USD","LU2210149790.SGD","BK4504","IE00B64PRP62.GBP","LU1868837300.USD","IE0034235188.USD","LU1791807156.HKD","IE00B19Z3B42.SGD","LU0061475181.USD","LU2095319765.USD","LU0868494617.USD","IE00BN0W2T93.GBP","LU2237443895.HKD","IE00B19Z3581.USD","BK4533","LU0314104364.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","LU0048573561.USD","LU1868837136.USD","GSX","LU1894683348.USD","LU1804176565.USD","LU2471134523.USD","IE00BGHQF748.EUR","BK4127","LU0106831901.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636645138","title":"Rhythm Pharma Controller, CAO Christopher Paul German disposes 4,643 shares worth $428,131.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2636645138","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636645138?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:17","pubTimestamp":1779221821,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals officer Christopher Paul German, corporate controller and CAO, reported selling out of his common stock position on May 15, 2026.The filing showed sales of 4,643 shares at USD 92.21, cutting his direct holdings to zero.The transactions followed option exercises for 4,442 shares at strike prices ranging from USD 17.97 to USD 56.69.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDLcc8sr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rhythm Pharma Controller, CAO Christopher Paul German disposes 4,643 shares worth $428,131.03","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635565170","title":"Expanded EU IMCIVREE Label for Hypothalamic Obesity Could Be A Game Changer For Rhythm (RYTM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635565170","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635565170?lang=en_us&edition=fundamental","pubTime":"2026-05-16 06:53","pubTimestamp":1778885626,"startTime":"0","endTime":"0","summary":"In early May 2026, Rhythm Pharmaceuticals reported first-quarter revenue of US$60.11 million and a net loss of US$55.64 million, while also securing European Commission approval to expand IMCIVREE (setmelanotide) for acquired hypothalamic obesity and presenting longer-term efficacy and safety data across pediatric and adult populations.\nThe new data presentations and broadened regulatory label for setmelanotide highlight growing clinical evidence in rare neuroendocrine obesity disorders and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/expanded-eu-imcivree-label-for-hypothalamic-obesity-could-be","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/expanded-eu-imcivree-label-for-hypothalamic-obesity-could-be","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RYTM","BK4139","BK4588","BK4585","BK4156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634799216","title":"Rhythm says setmelanotide cuts BMI 16.9% at 12 months in acquired hypothalamic obesity study","url":"https://stock-news.laohu8.com/highlight/detail?id=2634799216","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634799216?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:04","pubTimestamp":1778587467,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals flagged new real-world analyses and Phase 3 post hoc results for setmelanotide in acquired hypothalamic obesity, presented at European Congress of Endocrinology in May 2026.Real-world early-access experience in France showed sustained weight loss with improvements in patient-reported hunger, supporting effectiveness outside controlled trials.Separate Phase 3 analyses indicated broader cardiometabolic risk improvements versus placebo, extending treatment impact beyond weight reduction.Additional research in Bardet-Biedl syndrome suggested severe hyperphagia is frequently under-recognized when assessed only by self-reported questionnaires, pointing to a measurement gap that could affect diagnosis and care.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLblBJvS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","NDAQ","IE00BN0W2T93.GBP","BK4139","IE00BGHQF748.EUR","BK4588","BK4112","SG9999014005.SGD","LU0314104364.USD","BK4585","LU2210150020.SGD","IE00BN0W2W23.USD","SG9999014039.USD","RYTM","IE00BKPKM429.USD","SG9999014021.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634928612","title":"Guggenheim Remains a Buy on Rhythm Pharmaceuticals (RYTM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634928612","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634928612?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:55","pubTimestamp":1778500507,"startTime":"0","endTime":"0","summary":"In a report released today, Seamus Fernandez from Guggenheim reiterated a Buy rating on Rhythm Pharmaceuticals, with a price target of $143.00. Acc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-rhythm-pharmaceuticals-rytm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-rhythm-pharmaceuticals-rytm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","BK4588","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633983458","title":"iBio names Elizabeth Stoner to board as Schimmelpennink steps down","url":"https://stock-news.laohu8.com/highlight/detail?id=2633983458","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633983458?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:15","pubTimestamp":1778238922,"startTime":"0","endTime":"0","summary":"iBio appointed Elizabeth Stoner, M.D., M.S. to board as independent director.Stoner also joined Compensation Committee; Eef Schimmelpennink stepped down from board.Stoner is Entrepreneur Partner at MPM BioImpact; previously interim CEO at Semma Therapeutics.She also founded Rhythm Pharmaceuticals, serving as chief medical officer and chief development officer; earlier led global clinical development operations at Merck Research Laboratories.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL47yj1v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673691.USD","LU1069344957.HKD","IE00B894F039.SGD","LU2417539215.USD","SG9999001176.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","LU1093756325.SGD","LU2236285917.USD","RYTM","SG9999014005.SGD","VRTX","LU0314104364.USD","IE0002270589.USD","LU2362541273.HKD","LU1093756168.USD","SG9999001176.SGD","BK4112","IE00B19Z9P08.USD","IE00BFTCPJ56.SGD","LU0061475181.USD","LU0256863811.USD","BK4532","BK4533","LU2462157665.USD","BK4568","LU2456880835.USD","LU0079474960.USD","LU2362541513.USD","LU0823416689.USD","NDAQ","IE00B3QW5Z07.USD","LU0320765992.SGD","SGXZ57979304.SGD","IE00B64PRP62.GBP","BK4139","IE0002141913.USD","IBIO","IE00BN0W2V16.EUR","LU1585245621.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK4567","IE00B19Z3581.USD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","LU2237438978.USD","BK4585","LU0058720904.USD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633103216","title":"Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2633103216","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633103216?lang=en_us&edition=fundamental","pubTime":"2026-05-08 06:33","pubTimestamp":1778193180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 07, 2026 18:33 ET (22:33 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","RYTM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633812234","title":"Rhythm Pharmaceuticals price target raised to $143 from $140 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2633812234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633812234?lang=en_us&edition=fundamental","pubTime":"2026-05-08 00:30","pubTimestamp":1778171444,"startTime":"0","endTime":"0","summary":"Canaccord raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $143 from $140 and keeps a Buy rating on the shares. The firm said the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-price-target-raised-to-143-from-140-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-price-target-raised-to-143-from-140-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","RYTM","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633429153","title":"Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633429153","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633429153?lang=en_us&edition=fundamental","pubTime":"2026-05-07 02:04","pubTimestamp":1778090699,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/05/52337131/rhythm-pharmaceuticals-analysts-boost-their-forecasts-following-upbeat-q1-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633138181","title":"Rhythm Pharma CEO joins Bank of America Global Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2633138181","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633138181?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:05","pubTimestamp":1778069134,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals to participate in a fireside chat at Bank of America Global Healthcare Conference on May 13 at 3:00 p.m. PT in Las Vegas.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL8ncmFg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","RYTM","LU2210150020.SGD","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00B64PRP62.GBP","BK4139","LU0314104364.USD","BK4588","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BKPKM429.USD","NDAQ","LU2095319765.USD","SG9999014021.USD","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633180550","title":"Rhythm Pharmaceuticals (RYTM) Receives a Buy from Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2633180550","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633180550?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:30","pubTimestamp":1778067056,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Seamus Fernandez reiterated a Buy rating on Rhythm Pharmaceuticals today and set a price target of $143.00. Fernandez covers the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rhythm-pharmaceuticals-rytm-receives-a-buy-from-guggenheim-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rhythm-pharmaceuticals-rytm-receives-a-buy-from-guggenheim-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","RYTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633940230","title":"BUZZ-U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel","url":"https://stock-news.laohu8.com/highlight/detail?id=2633940230","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633940230?lang=en_us&edition=fundamental","pubTime":"2026-05-06 02:06","pubTimestamp":1778004390,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, IntelWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call n","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL6N41I0HB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDXX","SNDK","DOCN","PFE","HII","BRBR","EXPD","DUOL","HSIC","ETN","AU","MED","PSKY","IQV","PLTR","EMBC","NEM","MASK","GPK","DFIN","MPC","NOW","SKK","WAT","SLQT","RYTM","PYPL","SDOT","SHLS","DD","ON","TDG","ULTA","ONIT","AMD","VRDN","PINS","FSEA","GFS","COIN","RVTY","WGS","BLZE","REPL","SHOP","STRL","KOS","BLSH","FISV","INTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633428609","title":"Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Viridian Therapeutics (VRDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633428609","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633428609?lang=en_us&edition=fundamental","pubTime":"2026-05-06 00:01","pubTimestamp":1777996864,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rhythm Pharmaceuticals (RYTM) and Viridian Therapeut...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-rhythm-pharmaceuticals-rytm-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-rhythm-pharmaceuticals-rytm-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","XBI","LU0029874061.USD","XLV","RYTM","HCSG","BK4588","BK4581","BK4137","BK4139","VRDN","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173386892","title":"Stock Track | Rhythm Pharmaceuticals Soars 12.79% Intraday on Better-Than-Expected Q1 Results Driven by IMCIVREE Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=1173386892","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173386892?lang=en_us&edition=fundamental","pubTime":"2026-05-05 21:51","pubTimestamp":1777989107,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. (RYTM) saw its stock price soar 12.79% during intraday trading on Tuesday.The significant move higher follows the company's release of its first quarter 2026 financial...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633894578","title":"Rhythm Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633894578","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633894578?lang=en_us&edition=fundamental","pubTime":"2026-05-05 21:31","pubTimestamp":1777987896,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryRhythm Pharmaceuticals Inc RYTM.OQ reported a quarterly adjusted loss of 83 cents per share for the quarter ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL8N41I1TQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633948220","title":"Rhythm Pharmaceuticals Shares up 7.5% Premarket After Q1 Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2633948220","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633948220?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:35","pubTimestamp":1777984528,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL4N41I14J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RYTM","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633917617","title":"Rhythm Pharmaceuticals Q1 revenue rises 84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633917617","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633917617?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:36","pubTimestamp":1777980978,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Q1 revenue rises 84%OverviewU.S. biopharma's Q1 product revenue rose 83.8% yr/yr on IMCIVREE uptakeQ1 net loss came in slightly wider than analyst expectationsCompany launched I","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL1N41I0FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","RYTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rhythmtx.com","stockEarnings":[{"period":"1week","weight":0.0416},{"period":"1month","weight":-0.067},{"period":"3month","weight":-0.024},{"period":"6month","weight":-0.253},{"period":"1year","weight":0.3168},{"period":"ytd","weight":-0.1792}],"compareEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.0898},{"period":"6month","weight":0.0695},{"period":"1year","weight":0.2291},{"period":"ytd","weight":0.0808}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.051908},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.048958},{"month":3,"riseRate":0.111111,"avgChangeRate":-0.056668},{"month":4,"riseRate":0.555556,"avgChangeRate":0.013671},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045608},{"month":6,"riseRate":0.444444,"avgChangeRate":0.04077},{"month":7,"riseRate":0.5,"avgChangeRate":0.281728},{"month":8,"riseRate":0.75,"avgChangeRate":0.239414},{"month":9,"riseRate":0.375,"avgChangeRate":-0.040591},{"month":10,"riseRate":0.375,"avgChangeRate":-0.015139},{"month":11,"riseRate":0.777778,"avgChangeRate":0.136999},{"month":12,"riseRate":0.555556,"avgChangeRate":0.041318}],"exchange":"NASDAQ","name":"Rhythm Pharmaceuticals Inc.","nameEN":"Rhythm Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rhythm Pharmaceuticals Inc.(RYTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rhythm Pharmaceuticals Inc.,RYTM,Rhythm Pharmaceuticals Inc.股票,Rhythm Pharmaceuticals Inc.股票老虎,Rhythm Pharmaceuticals Inc.股票老虎国际,Rhythm Pharmaceuticals Inc.行情,Rhythm Pharmaceuticals Inc.股票行情,Rhythm Pharmaceuticals Inc.股价,Rhythm Pharmaceuticals Inc.股市,Rhythm Pharmaceuticals Inc.股票价格,Rhythm Pharmaceuticals Inc.股票交易,Rhythm Pharmaceuticals Inc.股票购买,Rhythm Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rhythm Pharmaceuticals Inc.(RYTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}